Answers are grounded in this paper and cite their sources.
The combination of BRAF and tyrosine kinase (TK) inhibitors has been demonstrated to be highly effective in inhibiting tumor development and is an approach for overcoming resistance in clinical trials. Accordingly, a novel series of 1,2,4-oxadiazole/quinazoline-4-one hybrids was developed as antiproliferative multitargeted inhibitors.
No takes yet. Share an insight, caveat, or question.
Mohamed et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: